Clinical trials: Leucovorin, open to volunteers
Rectal Cancer
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together…
- Trial name
- NEO-RT (NCT06205485)
- Testing
- Leucovorin, Oxaliplatin, Fluoruracil
- Where
- 113 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Canadian Cancer Trials Group
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine)…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT06998940
- Testing
- Biospecimen Collection, Computed Tomography, Fluorouracil
- Where
- 274 sites in United States
- Volunteers
- 94 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer Metastatic
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
This prospective, randomized, controlled clinical study aims to evaluate the objective remission rate of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with systemic irinotecan with or without bevacizumab versus…
- Trial name
- NCT05727163
- Testing
- Dexamethasone, Anisodamine, Oxaliplatin
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
This is a prospective, single-center, single-arm clinical study. It aims to evaluate the efficacy and safety of a new combination therapy as a first-line treatment for patients with advanced intrahepatic cholangiocarcinoma (ICC)…
- Trial name
- NCT07432568
- Testing
- Hepatic Arterial Infusion Chemotherapy (HAIC) with Liposomal Irinotecan, 5-Fluorouracil, Leucovorin, Lenvatinib, PD-1 Inhibitor
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric or Gastroesophageal Junction Adenocarcinoma
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced…
- Trial name
- NCT06841679
- Testing
- Utidelone Capsule, Fluoropyrimidine- and Platinum-containing Therapy, Oxaliplatin
- Where
- 10 sites in United States, China
- Volunteers
- 778 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Pancreatic Cancer
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
This study is a prospective, single-arm, two-cohort phase II clinical study. It is expected to enroll 48 patients with advanced or metastatic pancreatic cancer who have failed prior treatment with irinotecan-containing regimens…
- Trial name
- NCT06700603
- Testing
- Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
- Volunteers
- 48 people
- Sponsor
- Rui-hua Xu, MD, PhD
Borderline Resectable Pancreatic Ductal Adenocarcinoma
NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
This phase II trial tests how well liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) before surgery works in treating patients with pancreatic ductal adenocarcinoma that is close to major blood vessels…
- Trial name
- NCT06821997
- Testing
- Biospecimen Collection, Computed Tomography, Fluorouracil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Older Patients, Colorectal Cancer
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
The goal of this phase III, open-label, non-inferiority randomized controlled clinical trial is compare upfront dose-reduced chemotherapy with the standard dose chemotherapy in older patients ( ≥70 years) with metastasized…
- Conditions
- Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy
- Trial name
- DOSAGE (NCT06275958)
- Testing
- Doublet Chemotherapy, Standard Dose (100%), Doublet Chemotherapy, Dose-reduced (75%), Monotherapy, Standard Dose (100%)
- Where
- 36 sites in Netherlands
- Volunteers
- 587 people
- Sponsor
- Leiden University Medical Center
Ampulla of Vater Carcinoma, Appendix Carcinoma
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
This clinical trial is being done to learn whether using the proactive, graduated dose modification algorithm for leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) (PAGODA) algorithm to guide chemotherapy dosing for the…
- Conditions
- Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile, Colon Carcinoma
- Trial name
- NCT07283939
- Testing
- PAGODA algorithm, Oxaliplatin, Folinic Acid
- Where
- 398 sites in United States, Guam and 1 more
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Tumors
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.
- Trial name
- NCT06703177
- Testing
- SHR-1826, SHR-4642, SHR-9839
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers.
- Conditions
- Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06428409
- Testing
- Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
CRC, Liver Metastasis Colon Cancer
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
This prospective study aims to investigate the efficacy and safety of peritumoral injection of the oncolytic virus H101 in combination with stereotactic body radiotherapy (SBRT), PD-1 monoclonal antibody, chemotherapy, and…
- Trial name
- VVSHIP (NCT07381309)
- Testing
- SBRT, PD-1 Antibody, H101
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Jun Huang
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric…
- Trial name
- NCT07043400
- Testing
- Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin
- Where
- 95 sites in United States, Argentina and 14 more
- Volunteers
- 351 people
- Sponsor
- BeOne Medicines
Small-bowel Adenocarcinoma, Metastatic Disease
First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma
Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
- Conditions
- Small-bowel Adenocarcinoma, Metastatic Disease, Chemotherapy Effect
- Trial name
- FIRE-12 (NCT07844057)
- Testing
- mFOLFIRINOX versus FOLFOX chemotherapy
- Where
- 16 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Annika Kurreck
Colo-rectal Cancer
Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer
This is a non-registrational Phase 1/2, multicenter, open-label trial to evaluate the efficacy and safety of varsetatug masetecan combined with anti-cancer therapies in participants with unresectable metastatic colorectal cancer…
- Trial name
- NCT07900165
- Testing
- varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab
- Volunteers
- 368 people
- Sponsor
- CytomX Therapeutics
Autism Spectrum Disorder, Language Disorders
Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism
The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves social communication as…
- Trial name
- NCT04060030
- Testing
- Levoleucovorin Calcium
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Southwest Autism Research & Resource Center
Locally Advanced or Metastatic Small Bowel Adenocarcinoma
Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma
Randomized, non-comparative, open-label, multi-centre Phase II study to evaluate modified FOLFIRINOX and modified FOLFOX in the locally advenced or metastatic small bowel adenocarcinoma.
- Trial name
- FOLFORINOX SBA (NCT06278545)
- Testing
- modified FOLFORINOX, Modified FOLFOX
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Locally Advanced Pancreatic Cancer, Irreversible Electroporation
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
Background Pancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally advanced pancreatic cancer and are not candidate for…
- Trial name
- SMART (NCT04276857)
- Testing
- Irreversible electroporation (NanoKnife® )
- Where
- 2 sites in Canada
- Volunteers
- 27 people
- Sponsor
- University of Saskatchewan
Colorectal Neoplasms
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer.
- Trial name
- MOUNTAINEER-03 (NCT05253651)
- Testing
- tucatinib, trastuzumab, bevacizumab
- Where
- 366 sites in United States, Argentina and 23 more
- Volunteers
- 400 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
- Trial name
- NCT06172205
- Testing
- intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University